Tempest Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$26.6M | -$42.0M | -$29.2M | -$34.6M | -$27.0M |
| Cash from operations | -$26.8M | -$33.0M | -$27.4M | -$31.1M | -$26.0M |
| Capital expenditure | $0 | $435,000 | $170,000 | $562,000 | $135,000 |
| Free cash flow | -$26.8M | -$33.5M | -$27.5M | -$31.6M | -$26.1M |
| Total assets | $16.9M | $41.5M | $51.6M | $46.1M | $73.2M |
| Total liabilities | $10.3M | $22.4M | $24.8M | $28.0M | $37.1M |
Shares outstanding 14.8M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.